Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Vernon

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|November 30, 2006
Letter from the commissioner's office at the US FDAJohn A Vernon
Pharmacoeconomics|January 26, 2007
Letter from the Commissioner's Office at the US FDAJohn A Vernon
Expert Opinion on Drug Discovery|March 14, 2013
Considering the economic principles of pharmaceutical R&DJohn A Vernon
Pharmacoeconomics|July 6, 2007
Perspectives on dynamic optimisation and control theory in treating hyperlipidaemiaJohn A Vernon
Pharmacoeconomics|December 29, 2006
Letter from the Commissioner's office at the US FDAJohn A Vernon
Pharmacoeconomics|April 4, 2007
Letter from the Commissioner's Office at the US FDAJohn A Vernon
Health Economics|September 24, 2004
Examining the link between price regulation and pharmaceutical R&D investmentJohn A Vernon
Applied Health Economics and Health Policy|October 6, 2009
Financial risk of the biotech industry versus the pharmaceutical industryJoseph Golec, John A Vernon
Pharmacoeconomics|July 13, 2010
Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firmsJoseph Golec, John A Vernon
Inquiry : a Journal of Medical Care Organization, Provision and Financing|March 15, 2008
Ownership form and consumer welfare: evidence from the nursing home industryRexford E Santerre, John A Vernon
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|November 30, 2006
Letter from the commissioner's office at the US FDAJohn A Vernon
Pharmacoeconomics|January 26, 2007
Letter from the Commissioner's Office at the US FDAJohn A Vernon
Expert Opinion on Drug Discovery|March 14, 2013
Considering the economic principles of pharmaceutical R&DJohn A Vernon
Pharmacoeconomics|July 6, 2007
Perspectives on dynamic optimisation and control theory in treating hyperlipidaemiaJohn A Vernon
Pharmacoeconomics|December 29, 2006
Letter from the Commissioner's office at the US FDAJohn A Vernon
Pharmacoeconomics|April 4, 2007
Letter from the Commissioner's Office at the US FDAJohn A Vernon
Health Economics|September 24, 2004
Examining the link between price regulation and pharmaceutical R&D investmentJohn A Vernon
Applied Health Economics and Health Policy|October 6, 2009
Financial risk of the biotech industry versus the pharmaceutical industryJoseph Golec, John A Vernon
Pharmacoeconomics|July 13, 2010
Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firmsJoseph Golec, John A Vernon
Inquiry : a Journal of Medical Care Organization, Provision and Financing|March 15, 2008
Ownership form and consumer welfare: evidence from the nursing home industryRexford E Santerre, John A Vernon
Pageof 3